|
IQVIA™ Real-World Insights Bibliography
| The longitudinal relationship between fatigue, depression, anxiety, disability, and adherence with cognitive status in patients with early multiple sclerosis treated with interferon beta-1a
|
| Author(s): Hanne van Ballegooijen, Karin van der Hiele, Christian Enzinger, Gert de Voer, Leo H. Visser, on behalf of the CONFIDENCE Study Group |
| Affiliations(s): IQVIA Netherlands, Real World Evidence, Netherlands
b
Department of Psychology, Health, Medical and Neuropsychology Unit, Leiden University, Leiden, Netherlands
c
Medical University of Graz, Graz, Austria
d
Merck BV, Schiphol-Rijk, The Netherlands, an affiliate of Merck KGaA, Germany
e
St Elisabeth Tweesteden Hospital, Tilburg, the Netherlands |
Publication(s): eNeurologicalSci,
Volume 28,
2022,
100409,
ISSN 2405-6502,
https://doi.org/10.1016/j.ensci.2022.100409.
(https://www.sciencedirect.com/science/article/pii/S2405650222000181)
|
| Document Type(s): Article, |
| Countries: Austria, Belgium, Netherlands , Slovakia, |
| Click here for the abstract |
C:
Y: |
Drug safety, Drug Utlization Study, Neurological disorders,
2022 |
|
L:
A: |
English
Clinical setting: hospital, clinical setting: Secondary care, Epidemiological study, Population Based Study, Prospective study, |
|
 |
| |
| |
| A Survey Among Health Care Professionals to Assess Their Knowledge and Understanding on Darzalex® (Daratumumab)
Educational Materials Regarding the Risk of Interference for Blood Typing in 12 European Countries |
| Author(s): Mathieu Rosé, Intissar Bourahla, Alessandro Ghiddi, Assem Al-Akabawi, Edmond Chan, Massoud Toussi |
| Affiliations(s): IQVIA, Courbevoie, France;
Janssen EMEA, Medical Affairs, Italy;
Janssen EMEA, Medical Affairs, UK |
Publication(s): Presented at ISPE’s 35th International Conference on Pharmacoepidemiology and Therapeutic Risk
Management (ICPE 2019), August 24–28, 2019 at the Pennsylvania Convention Center, Philadelphia, PA, USA.
|
| Document Type(s): Poster, |
| Countries: Austria, Czech, Denmark, Finland, France, Germany, Hungary, Norway, Slovakia, Spain, Sweden, Switzerland, |
| Click here for the abstract |
C:
Y: |
Hematology, Oncology,
2019 |
|
L:
A: |
English
Public Health, Survey research, |
|
|
| |
| |
| Patient and caregiver indirect costs after acute cardiovascular events in Europe. |
| Author(s): Sidelnikov E1, Gerlier L2, Kutikova L1, Amarenco P3, Kotseva K4, Annemans L5 |
| Affiliations(s): 1 Amgen (Europe) GmbH, Zug, Switzerland 2 IQVIA, Zaventem, Belgium 3 Paris-Diderot-Sorbonne University, Paris, France 4 National Heart & Lung Institute, Imperial College London, London, UK 5 Ghent University, Ghent, Belgium |
Publication(s): ISPOR 21st Annual European Congress, 2018, November 10-14, Barcelona, Spain
|
| Document Type(s): Oral presentation, |
| Countries: Austria, Bulgaria, Croatia, Czech, Denmark, Finland, Germany, Greece, Italy, Norway, Romania, Slovakia, Slovenia, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Health economics,
2018 |
|
L:
A: |
English
Burden of illness, Cost of illness, |
|
|
| |
| |
| Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature. |
| Author(s): Svedman FC1, Pillas D2, Taylor A2, Kaur M2, Linder R3, Hansson J1. |
| Affiliations(s): 1Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden.
2Centre for Observational Research, Amgen Ltd, Uxbridge, UK.
3IMS Health Sweden, Stockholm, Sweden.
|
Publication(s): Clinical Epidemiology
|
| Document Type(s): Article, |
| Countries: Australia, Austria, Belgium, Bulgaria, Croatia, Czech, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, Norway, Poland, Portugal, Russian Federation, Serbia and Montenegro, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, UK, |
| Click here for the abstract |
C:
Y: |
Oncology,
2016 |
|
L:
A: |
English
Literature Review, |
|
|
| |
| |
| Cost analysis: treatment of chemotherapy-induced anemia with erythropoiesis-stimulating agents in five European countries |
| Author(s): Duran A1, Spaepen E2,Lamotte M3, Walter E4, Umuhire D5, Lucioni C6, Pinheir B7, Brosa M8, Pujol LKB9, Van Belle S10, Annemans L11 |
| Affiliations(s): 1 IMS Health, London, UK 2 SBD Analytics BVBA/SPRL, Bekkevoort, Belgium 3 IMS
Health, Vilvoorde, Belgium 4 Institute for Pharmaeconomic Research, Health
Economics, Vienna, Austria 5 IMS Health, Paris, France 6 Wolters Kluwer Health Italy, Milan, Italy 7 CISEP, Research Centre on the Portuguese Economy,
Lisbon, Portugal 8 Oblikue Consulting, Barcelona, Spain 9 Amgen (Europe) GmbH, Zug, Switzerland 10 Department of Medical Oncology, Ghent University
Hospital, Ghent, Belgium 11 I-CHER, Ghent University, Brussels University (VUB),
Ghent, Belgium |
Publication(s): Journal of Medical Economics Vol. 15, No. 3, 2012, 1–10
|
| Document Type(s): Article, |
| Countries: Austria, Belgium, France, Italy, Spain, |
C:
Y: |
Hematology,
2012 |
|
L:
A: |
English
Cost analysis, |
|
|
| |
| |
| Cost analysis of anemia treatment with erythropoieses-stimulating agents (ESAs) in patients with cancer receiving chemotherapy: a multi-country approach. |
| Author(s): Duran A1, Spaepen E2, Lamotte M3, Walter E4, Lucioni C5, Pinheiro B6, Brosa M7, Kutikova L8, Pujol B8, Annemans L9 |
| Affiliations(s): 1 IMS Health, London, United Kingdom 2 SBD Analytics, Belgium 3 IMS Health, Vilvoorde, Belgium 4 Institute for Parmacoeconomic Research, Vienna, Austria 5 Wolters Kluwer Health Italy, Milan, Italy 6 Centre de Investigaçao Sobre Economia Portuguesa, Lisboa, Portugal 7 Oblikue Consulting, Barcelona, Spain 8 Amgen (Europe), Zug, Switzerland 9 I-CHER Interuniversity Centre for Health Economics Research, Gent, Belgium |
Publication(s): ISPOR 14th Annual European Congress
5-8 November 2011, Madrid, Spain
|
| Document Type(s): Poster, |
| Countries: Austria, Italy, Portugal, Spain, |
C:
Y: |
Oncology,
2011 |
|
L:
A: |
English
Cost analysis, |
|
|
| |
| |
| Cost Analysis of Anaemia Treatment With Erythropoiesis-Stimulating Agents in Cancer Patients Receiving Chemotherapy |
| Author(s): Duran A1, Spaepen E2, Lamotte M3, Walter E4, Kutikova L5, Pujol B5, Ribnicsek E6, Annemans L7 |
| Affiliations(s): 1IMS Health, London, UK; 2SBD Analytics BVBA/SPRL, Belgium; 3IMS Health, Vilvoorde, Belgium; 4Institut für Pharmaökonomische Forschung, Vienna, Austria; 5Amgen (Europe) GmbH, Zug, Switzerland; 6Amgen, Vienna, Austria; 7I-CHER Interuniversity Centre for Health Economics Research, UGent, VUB, Belgium |
Publication(s): 16th Congress of the European Association of Hospital Pharmacists, 30 March - 1 April 2011.
|
| Document Type(s): Poster, |
| Countries: Austria, Belgium, |
C:
Y: |
Oncology,
2011 |
|
L:
A: |
English
Cost analysis, |
|
|
| |
| |
| Economic evaluation of Ranibizumab in the treatment of visual impairment due to diabetic macular edema in Austria |
| Author(s): Brennig C1, Schöllbauer V1, Walter E1, Gallagher M2, Knudsen MS3
|
| Affiliations(s): 1Institute for Pharmaeconomic Research, Vienna, Austria, 2Novartis Pharma AG, Basel, Switzerland, 3IMS Health, London, UK |
Publication(s): ISPOR 14th Annual European Congress, 5th - 8th November, Madrid, Spain
|
| Document Type(s): Poster, |
| Countries: Austria, |
| Click here for the abstract |
C:
Y: |
Diabetes,
2011 |
|
L:
A: |
English
Economic evaluation, |
|
|
| |
| |
| Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. |
| Author(s): Jose´ R. Banegas 1,2*, Esther Lo´pez-Garcı´a 1,2, Jean Dallongeville3, Eliseo Guallar 4,5,6,7,
Julian P. Halcox8, Claudio Borghi 9, Elvira L. Masso´-Gonza´lez 10,
Francisco J. Jime´nez 11, Joep Perk12, Philippe Gabriel Steg13, Guy De Backer 14,and Fernando Rodrı´guez-Artalejo1,2 |
| Affiliations(s): 1
Department of Preventive Medicine and Public Health, School of Medicine, Universidad Auto´noma de Madrid/IdiPAZ, Avda Arzobispo Morcillo, 2, 28029 Madrid, Spain; 2
CIBER of
Epidemiology and Public Health, Madrid, Spain; 3
Inserm U 744, Institut Pasteur de Lille, 59019 Lille Cedex, France; 4
Department of Epidemiology, Johns Hopkins Bloomberg School
of Public Health, Baltimore, MD 21205, USA; 5
Department of Medicine, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA; 6
Welch Center for
Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA; 7
Department of Cardiovascular Epidemiology and
Population Genetics, National Center for Cardiovascular Research (CNIC), Madrid 28029, Spain; 8
Wales Heart Research Institute, Cardiff University, Heath Park, Cardiff CF14 4XN,
UK; 9
Department of Internal Medicine, Aging and Clinical Nephrology, University of Bologna, Bologna, Italy; 10Medical Department, AstraZeneca Farmace´utica Spain, S.A., 28003
Madrid, Spain; 11Medical Department, AstraZeneca Europe, 1935 Zaventem, Belgium; 12School of Health and Caring Sciences, Linnaeus University, 391 82 Kalmar, Sweden; 13INSERM U 698, Assistance Publique–Hoˆpitaux de Paris and Universite´ Paris-Diderot, Paris, France; and 14Department of Public Health, University of Gent, 9000 Gent, Belgium |
Publication(s): Eur Heart J. 2011 Sep;32(17):2143-52
|
| Document Type(s): Article, |
| Countries: Austria, Belgium, France, Germany, Greece, Norway, Spain, Sweden, Switzerland, Turkey, UK, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease,
2011 |
|
L:
A: |
English
Observational study, Prospective study, |
|
|
| |
| |
| Excess risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe - The EURIKA Study. |
| Author(s): Guallar E, Banegas JR, Blasco-Colmenares E, Jiménez FJ, Dallongeville J, Halcox JP, Borghi C, Massó-González EL, Tafalla M, Perk J, De Backer G, Steg PG, Rodríguez-Artalejo F. |
| Affiliations(s): |
Publication(s): BMC Public Health. 2011 Sep 18;11:704. doi: 10.1186/1471-2458-11-704.
|
| Document Type(s): Article, |
| Countries: Austria, Belgium, France, Germany, Greece, Norway, Russian Federation, Spain, Sweden, Switzerland, Turkey, UK, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease,
2011 |
|
L:
A: |
English
Observational study, Prospective study, |
|
|
| |
| |
 1 of 2 
|
|
